Cardiovascular Disease in Patients with Chronic Kidney Disease

Chronic Kidney Disease, Dialysis, and Transplantation

Volumn , Issue , 2010, Pages 128-144

  Weiner, Daniel E ^a   Sarnak, Mark J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882539540     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-0987-2.00010-8     Document Type: Chapter

References (246)

1. U.S. Renal Data System, USRDS 2008, Annual Data Report Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2008, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
2. Kung H.C., Hoyert D.L., Xu J., et al. Deaths: Final data for 2005 2008, vol. 56. National Center for Health Statistics, Hyattsville, MD, National Vital Statistics Report.
3. Herzog C.A., Ma J.Z., Collins A.J. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N. Engl. J. Med. 1998, 339(12):799-805.
4. Herzog C.A., Littrell K., Arko C., et al. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation 2007, 116(13):1465-1472.
5. Levin A., Singer J., Thompson C.R., et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am. J. Kidney Dis. 1996, 27(3):347-354.
6. Collins A.J., Foley R.N., Herzog C., et al. United States Renal Data System 2008 Annual Data Report Abstract. Am. J. Kidney Dis. 2009, 53(Suppl. 1):vi-vii. S8-S374.
7. Shlipak M.G., Simon J.A., Grady D., et al. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J. Am. Coll. Cardiol. 2001, 38(3):705-711.
8. Shlipak M.G., Heidenreich P.A., Noguchi H., et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann. Intern. Med. 2002, 137(7):555-562.
9. Wright R.S., Reeder G.S., Herzog C.A., et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann. Intern. Med. 2002, 137(7):563-570.
10. Henry R.M., Kostense P.J., Bos G., et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int. 2002, 62(4):1402-1407.
11. Manjunath G., Tighiouart H., Coresh J., et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003, 63(3):1121-1129.
12. Manjunath G., Tighiouart H., Ibrahim H., et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J. Am. Coll. Cardiol. 2003, 41(1):47-55.
13. Weiner D.E., Tabatabai S., Tighiouart H., et al. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am. J. Kidney Dis. 2006, 48(3):392-401.
14. Culleton B.F., Larson M.G., Wilson P.W., et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999, 56(6):2214-2219.
15. Garg A.X., Clark W.F., Haynes R.B., House A.A. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int. 2002, 61(4):1486-1494.
16. Kurth T., de Jong P.E., Cook N.R., et al. Kidney function and risk of cardiovascular disease and mortality in women: a prospective cohort study. BMJ 2009, 338:b2392.
17. Anavekar N.S., McMurray J.J., Velazquez E.J., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N. Engl. J. Med. 2004, 351(13):1285-1295.
18. Weiner D.E., Tighiouart H., Amin M.G., et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J. Am. Soc. Nephrol. 2004, 15(5):1307-1315.
19. Weiner D.E., Tighiouart H., Stark P.C., et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am. J. Kidney Dis. 2004, 44(2):198-206.
20. Dries D.L., Exner D.V., Domanski M.J., et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 2000, 35(3):681-689.
21. Mann J.F., Gerstein H.C., Pogue J., et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann. Intern. Med. 2001, 134(8):629-636.
22. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004, 351(13):1296-1305.
23. Tonelli M., Wiebe N., Culleton B., et al. Chronic kidney disease and mortality risk: a systematic review. J. Am. Soc. Nephrol. 2006, 17(7):2034-2047.
24. Wachtell K., Olsen M.H., Dahlof B., et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J. Hypertens. 2002, 20(3):405-412.
25. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993, 329(14):977-986.
26. Weiner D.E., Bartolomei K., Scott T., et al. Albuminuria, cognitive functioning, and white matter hyperintensities in homebound elders. Am. J. Kidney Dis. 2009, 53(3):438-447.
27. Culleton B.F., Larson M.G., Parfrey P.S., et al. Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. Am. J. Med. 2000, 109(1):1-8.
28. Kannel W.B., Stampfer M.J., Castelli W.P., Verter J. The prognostic significance of proteinuria: the Framingham study. Am. Heart J. 1984, 108(5):1347-1352.
29. Mogensen C.E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N. Engl. J. Med. 1984, 310(6):356-360.
30. Bigazzi R., Bianchi S., Baldari D., Campese V.M. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J. Hypertens. 1998, 16(9):1325-1333.
31. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 2002, 39(2 Suppl. 1):S1-S266.
32. Wang T.J., Gona P., Larson M.G., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med. 2006, 355(25):2631-2639.
33. Hillege H.L., Fidler V., Diercks G.F., et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002, 106(14):1777-1782.
34. Romundstad S., Holmen J., Kvenild K., et al. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trondelag Health Study (HUNT), Norway. Am. J. Kidney Dis. 2003, 42(3):466-473.
35. Gerstein H.C., Mann J.F., Yi Q., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286(4):421-426.
36. Wachtell K., Ibsen H., Olsen M.H., et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann. Intern. Med. 2003, 139(11):901-906.
37. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97(18):1837-1847.
38. Weiner D.E., Tighiouart H., Griffith J.L., et al. Kidney disease, Framingham risk scores, and cardiac and mortality outcomes. Am. J. Med. 2007, 120(6):552 e1. 552 e8.
39. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108(17):2154-2169.
40. Weiner D.E., Tighiouart H., Elsayed E.F., et al. The framingham predictive instrument in chronic kidney disease. J. Am. Coll. Cardiol. 2007, 50(3):217-224.
41. Patel U.D., Ou F.S., Ohman E.M., et al. Hospital performance and differences by kidney function in the use of recommended therapies after non-ST-elevation acute coronary syndromes. Am. J. Kidney Dis. 2009, 53(3):426-437.
42. Weiner D.E., Sarnak M.J. Microalbuminuria: A marker of cardiovascular risk. Am. J. Kidney Dis. 2003, 42(3):596-598.
43. Longenecker J.C., Coresh J., Powe N.R., et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J. Am. Soc. Nephrol. 2002, 13(7):1918-1927.
44. Uhlig K., Levey A.S., Sarnak M.J. Traditional cardiac risk factors in individuals with chronic kidney disease. Semin. Dial. 2003, 16(2):118-127.
45. Agarwal R., Nissenson A.R., Batlle D., et al. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am. J. Med. 2003, 115(4):291-297.
46. Port F.K., Hulbert-Shearon T.E., Wolfe R.A., et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am. J. Kidney Dis. 1999, 33(3):507-517.
47. Zager P.G., Nikolic J., Brown R.H., et al. "U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int. 1998, 54(2):561-569.
48. Stidley C.A., Hunt W.C., Tentori F., et al. Changing relationship of blood pressure with mortality over time among hemodialysis patients. J. Am. Soc. Nephrol. 2006, 17(2):513-520.
49. Foley R.N., Parfrey P.S., Harnett J.D., et al. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int. 1996, 49(5):1379-1385.
50. Kawamura M., Fijimoto S., Hisanaga S., et al. Incidence, outcome, and risk factors of cerebrovascular events in patients undergoing maintenance hemodialysis. Am. J. Kidney Dis. 1998, 31(6):991-996.
51. Palmer B.F., Henrich W.L. Recent advances in the prevention and management of intradialytic hypotension. J. Am. Soc. Nephrol. 2008, 19(1):8-11.
52. Tonelli M., Bohm C., Pandeya S., et al. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am. J. Kidney Dis. 2001, 37(3):484-489.
53. Coresh J., Wei G.L., McQuillan G., et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch. Intern. Med. 2001, 161(9):1207-1216.
54. Buckalew V.M., Berg R.L., Wang S.R., et al. Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group. Am. J. Kidney Dis. 1996, 28(6):811-821.
55. Adler A.I., Stratton I.M., Neil H.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321(7258):412-419.
56. Davis T.M., Millns H., Stratton I.M., et al. Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch. Intern. Med. 1999, 159(10):1097-1103.
57. Lazarus J.M., Bourgoignie J.J., Buckalew V.M., et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension 1997, 29(2):641-650.
58. Sarnak M.J., Greene T., Wang X., et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann. Intern. Med. 2005, 142(5):342-351.
59. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 1993, 329(20):1456-1462.
60. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001, 345(12):851-860.
61. Jafar T.H., Schmid C.H., Landa M., et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann. Intern. Med. 2001, 135(2):73-87.
62. Jafar T.H., Stark P.C., Schmid C.H., et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann. Intern. Med. 2003, 139(4):244-252.
63. Giatras I., Lau J., Levey A.S. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann. Intern. Med. 1997, 127(5):337-345.
64. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001, 345(12):861-869.
65. Carr A.A., Kowey P.R., Devereux R.B., et al. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am. J. Cardiol. 2005, 96(11):1530-1536.
66. Berl T., Hunsicker L.G., Lewis J.B., et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J. Am. Soc. Nephrol. 2005, 16(7):2170-2179.
67. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am. J. Kidney Dis. 2004, 43(5 Suppl. 1):S1-S290.
68. Attman P.O., Samuelsson O., Alaupovic P. Lipoprotein metabolism and renal failure. Am. J. Kidney Dis. 1993, 21(6):573-592.
69. Kalantar-Zadeh K., Block G., Humphreys M.H., Kopple J.D. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003, 63(3):793-808.
70. Liu Y., Coresh J., Eustace J.A., et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004, 291(4):451-459.
71. Lowrie E.G., Lew N.L. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am. J. Kidney Dis. 1990, 15(5):458-482.
72. Iseki K., Yamazato M., Tozawa M., Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002, 61(5):1887-1893.
73. Fellstrom B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 2009, 360(14):1395-1407.
74. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 2005, 353(3):238-248.
75. Tonelli M., Isles C., Curhan G.C., et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004, 110(12):1557-1563.
76. Tonelli M., Moye L., Sacks F.M., et al. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann. Intern. Med. 2003, 138(2):98-104.
77. Chonchol M., Cook T., Kjekshus J., et al. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am. J. Kidney Dis. 2007, 49(3):373-382.
78. Strippoli G.F., Navaneethan S.D., Johnson D.W., et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008, 336(7645):645-651.
79. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am. J. Kidney Dis. 2009, 54:810-819.
80. Asselbergs F.W., Diercks G.F., Hillege H.L., et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004, 110(18):2809-2816.
81. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am. J. Kidney Dis. 2003, 41(4 Suppl. 3):I-IV. S1-S92.
82. Baigent C., Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int. Suppl. 2003, (84):S207-S210.
83. Menon V., Wang X., Greene T., et al. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am. J. Kidney Dis. 2003, 42(1):44-52.
84. Sarnak M.J. Cardiovascular complications in chronic kidney disease. Am. J. Kidney Dis. 2003, 41(Suppl. 5):11-17.
85. Cheung A.K., Sarnak M.J., Yan G., et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000, 58(1):353-362.
86. Harnett J.D., Foley R.N., Kent G.M., et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int. 1995, 47(3):884-890.
87. Le Feuvre C., Borentain M., Beygui F., et al. Comparison of short- and long-term outcomes of coronary angioplasty in patients with and without diabetes mellitus and with and without hemodialysis. Am. J. Cardiol. 2003, 92(6):721-725.
88. Herzog C.A., Ma J.Z., Collins A.J. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 2002, 106(17):2207-2211.
89. Williams M.E., Lacson E., Teng M., et al. Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int. 2006, 70(8):1503-1509.
90. Kalantar-Zadeh K., Kopple J.D., Regidor D.L., et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care 2007, 30(5):1049-1055.
91. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am. J. Kidney Dis. 2005, 45(4 Suppl. 3):S1-S153.
92. Wilson P.W., Castelli W.P., Kannel W.B. Coronary risk prediction in adults (the Framingham Heart Study). Am. J. Cardiol. 1987, 59(14):91G-94G.
93. deFilippi C.W.S., Rosanio S., Tiblier E., et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003, 290(3):353-359.
94. Foley R.N., Parfrey P.S., Harnett J.D., et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995, 47(1):186-192.
95. Mitsnefes M.M., Daniels S.R., Schwartz S.M., et al. Changes in left ventricular mass in children and adolescents during chronic dialysis. Pediatr. Nephrol. 2001, 16(4):318-323.
96. Zoccali C., Benedetto F.A., Mallamaci F., et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J. Am. Soc. Nephrol. 2001, 12(12):2768-2774.
97. Parfrey P.S., Foley R.N., Harnett J.D., et al. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol. Dial. Transplant. 1996, 11(7):1277-1285.
98. Middleton R.J., Parfrey P.S., Foley R.N. Left ventricular hypertrophy in the renal patient. J. Am. Soc. Nephrol. 2001, 12(5):1079-1084.
99. Blacher J., Pannier B., Guerin A.P., et al. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 1998, 32(3):570-574.
100. Guerin A.P., London G.M., Marchais S.J., Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol. Dial. Transplant. 2000, 15(7):1014-1021.
101. McMahon L.P., Mason K., Skinner S.L., et al. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol. Dial. Transplant. 2000, 15(9):1425-1430.
102. Levin A., Thompson C.R., Ethier J., et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am. J. Kidney Dis. 1999, 34(1):125-134.
103. Kong C.H., Farrington K. Determinants of left ventricular hypertrophy and its progression in high-flux haemodialysis. Blood Purif. 2003, 21(2):163-169.
104. Ozkahya M., Toz H., Qzerkan F., et al. Impact of volume control on left ventricular hypertrophy in dialysis patients. J. Nephrol. 2002, 15(6):655-660.
105. Cridlig J., Selton-Suty C., Alla F., et al. Cardiac impact of the arteriovenous fistula after kidney transplantation: a case-controlled, match-paired study. Transpl. Int. 2008, 21(10):948-954.
106. Harnett J.D., Murphy B., Collingwood P., et al. The reliability and validity of echocardiographic measurement of left ventricular mass index in hemodialysis patients. Nephron 1993, 65(2):212-214.
107. Krenning B.J., Voormolen M.M., Geleijnse M.L., et al. Three-dimensional echocardiographic analysis of left ventricular function during hemodialysis. Nephron Clin. Pract. 2007, 107(2):c43-c49.
108. MacWalter R.S., Wong S.Y., Wong K.Y., et al. Does renal dysfunction predict mortality after acute stroke? A 7-year follow-up study. Stroke 2002, 33(6):1630-1635.
109. Hunold P., Vogt F.M., Heemann U.W., et al. Myocardial mass and volume measurement of hypertrophic left ventricles by MRI-study in dialysis patients examined before and after dialysis. J. Cardiovasc. Magn. Reson. 2003, 5(4):553-561.
110. Schocken D.D., Benjamin E.J., Fonarow G.C., et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2008, 117(19):2544-2565.
111. Paoletti E., Cassottana P., Bellino D., et al. Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. Am. J. Kidney Dis. 2002, 40(4):728-736.
112. Unger P., Wissing K.M., de Pauw L., et al. Reduction of left ventricular diameter and mass after surgical arteriovenous fistula closure in renal transplant recipients. Transplantation 2002, 74(1):73-79.
113. Chan C.T., Floras J.S., Miller J.A., et al. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int. 2002, 61(6):2235-2239.
114. Ayus J.C., Mizani M.R., Achinger S.G., et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J. Am. Soc. Nephrol. 2005, 16(9):2778-2788.
115. Foley R.N., Parfrey P.S., Morgan J., et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000, 58(3):1325-1335.
116. Roger S.D., McMahon L.P., Clarkson A., et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J. Am. Soc. Nephrol. 2004, 15(1):148-156.
117. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 2006, 355(20):2071-2084.
118. Levin A., Djurdjev O., Thompson C., et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am. J. Kidney Dis. 2005, 46(5):799-811.
119. US Department of Health and Human Services National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 2004, NIH Publication No. 04-5230. August.
120. Orth S.R., Hallan S.I. Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients-absence of evidence or evidence of absence?. Clin. J. Am. Soc. Nephrol. 2008, 3(1):226-236.
121. Foley R.N., Herzog C.A., Collins A.J. Smoking and cardiovascular outcomes in dialysis patients: The United States Renal Data System Wave 2 Study. Kidney Int. 2003, 63(4):1462-1467.
122. Himmelfarb J., Stenvinkel P., Ikizler T.A., Hakim R.M. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002, 62(5):1524-1538.
123. Sies H. Oxidative stress: oxidants and antioxidants. Exp. Physiol. 1997, 82(2):291-295.
124. Locatelli F., Canaud B., Eckardt K.U., et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol. Dial. Transplant. 2003, 18(7):1272-1280.
125. Meerwaldt R., Zeebregts C.J., Navis G., et al. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis. Am. J. Kidney Dis. 2009, 53(1):138-150.
126. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340(2):115-126.
127. Danesh J., Collins R., Appleby P., Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998, 279(18):1477-1482.
128. Qureshi A.R., Alvestrand A., Divino-Filho J.C., et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J. Am. Soc. Nephrol. 2002, 13(Suppl. 1):S28-S36.
129. Spittle M.A., Hoenich N.A., Handelman G.J., et al. Oxidative stress and inflammation in hemodialysis patients. Am. J. Kidney Dis. 2001, 38(6):1408-1413.
130. Snaedal S., Heimburger O., Qureshi A.R., et al. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. Am. J. Kidney Dis. 2009, 53:1024-1033.
131. Weiner D.E., Tighiouart H., Elsayed E.F., et al. Inflammation and cardiovascular events in individuals with and without chronic kidney disease. Kidney Int. 2008, 73(12):1406-1412.
132. Menon V., Greene T., Wang X., et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int. 2005, 68(2):766-772.
133. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008, 359(21):2195-2207.
134. Yusuf S., Dagenais G., Pogue J., et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000, 342(3):154-160.
135. Boaz M., Smetana S., Weinstein T., et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000, 356(9237):1213-1218.
136. Tepel M., van der Giet M., Statz M., et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003, 107(7):992-995.
137. Tsuruoka S., Kawaguchi A., Nishiki K., et al. Vitamin E-bonded hemodialyzer improves neutrophil function and oxidative stress in patients with end-stage renal failure. Am. J. Kidney Dis. 2002, 39(1):127-133.
138. Miyazaki H., Matsuoka H., Itabe H., et al. Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation 2000, 101(9):1002-1006.
139. Baylis C. Nitric oxide deficiency in chronic kidney disease. Am. J. Physiol. Renal Physiol. 2008, 294(1):F1-F9.
140. Fujii H., Takiuchi S., Kawano Y., Fukagawa M. Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients. Am. J. Hypertens. 2008, 21(6):650-656.
141. Fliser D., Kronenberg F., Kielstein J.T., et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J. Am. Soc. Nephrol. 2005, 16(8):2456-2461.
142. Ravani P., Tripepi G., Malberti F., et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J. Am. Soc. Nephrol. 2005, 16(8):2449-2455.
143. Young J.M., Terrin N., Wang X., et al. Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009, 4(6):1115-1120.
144. Zoccali C., Bode-Boger S., Mallamaci F., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001, 358(9299):2113-2117.
145. Nanayakkara P.W., Kiefte-de Jong J.C., ter Wee P.M., et al. Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD. Am. J. Kidney Dis. 2009, 53(1):41-50.
146. Panichi V., Mantuano E., Paoletti S., et al. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. J. Nephrol. 2008, 21(1):38-44.
147. Schmitt B., Wolters M., Kressel G., et al. Effects of combined supplementation with B vitamins and antioxidants on plasma levels of asymmetric dimethylarginine (ADMA) in subjects with elevated risk for cardiovascular disease. Atherosclerosis 2007, 193(1):168-176.
148. Bostom A.G., Silbershatz H., Rosenberg I.H., et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch. Intern. Med. 1999, 159(10):1077-1080.
149. Bostom A.G., Rosenberg I.H., Silbershatz H., et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann. Intern. Med. 1999, 131(5):352-355.
150. Friedman A.N., Bostom A.G., Selhub J., et al. The kidney and homocysteine metabolism. J. Am. Soc. Nephrol. 2001, 12(10):2181-2189.
151. Bonaa K.H., Njolstad I., Ueland P.M., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N. Engl. J. Med. 2006, 354(15):1578-1588.
152. Lonn E., Yusuf S., Arnold M.J., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N. Engl. J. Med. 2006, 354(15):1567-1577.
153. Albert C.M., Cook N.R., Gaziano J.M., et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 2008, 299(17):2027-2036.
154. Ebbing M., Bleie O., Ueland P.M., et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 2008, 300(7):795-804.
155. Toole J.F., Malinow M.R., Chambless L.E., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004, 291(5):565-575.
156. Jamison R.L., Hartigan P., Kaufman J.S., et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007, 298(10):1163-1170.
157. Block G.A., Raggi P., Bellasi A., et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007, 71(5):438-441.
158. London G.M., Guerin A.P., Marchais S.J., et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol. Dial. Transplant. 2003, 18(9):1731-1740.
159. Covic A., Gusbeth-Tatomir P., Goldsmith D.J. Arterial stiffness in renal patients: an update. Am. J. Kidney Dis. 2005, 45(6):965-977.
160. Covic A., Mardare N., Gusbeth-Tatomir P., et al. Increased arterial stiffness in children on haemodialysis. Nephrol. Dial. Transplant. 2006, 21(3):729-735.
161. El-Abbadi M., Giachelli C.M. Mechanisms of vascular calcification. Adv. Chronic Kidney Dis. 2007, 14(1):54-66.
162. Schoppet M., Shroff R.C., Hofbauer L.C., Shanahan C.M. Exploring the biology of vascular calcification in chronic kidney disease: what's circulating?. Kidney Int. 2008, 73(4):384-390.
163. Prie D., Urena Torres P., Friedlander G. Latest findings in phosphate homeostasis. Kidney Int. 2009, 75(9):882-889.
164. Mathew S., Tustison K.S., Sugatani T., et al. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J. Am. Soc. Nephrol. 2008, 19(6):1092-1105.
165. Stubbs J.R., Liu S., Tang W., et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J. Am. Soc. Nephrol. 2007, 18(7):2116-2124.
166. Neves K.R., Graciolli F.G., dos Reis L.M., et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int. 2007, 71(12):1262-1270.
167. Mathew S., Lund R.J., Chaudhary L.R., et al. Vitamin D receptor activators can protect against vascular calcification. J. Am. Soc. Nephrol. 2008, 19(8):1509-1519.
168. Tentori F., Blayney M.J., Albert J.M., et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 2008, 52(3):519-530.
169. Wolf M., Shah A., Gutierrez O., et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007, 72(8):1004-1013.
170. Wolf M., Betancourt J., Chang Y., et al. Impact of activated vitamin D and race on survival among hemodialysis patients. J. Am. Soc. Nephrol. 2008, 19(7):1379-1388.
171. Shoben A.B., Rudser K.D., de Boer I.H., et al. Association of oral calcitriol with improved survival in nondialyzed CKD. J. Am. Soc. Nephrol. 2008, 19(8):1613-1619.
172. Isakova T., Gutierrez O.M., Chang Y., et al. Phosphorus binders and survival on hemodialysis. J. Am. Soc. Nephrol. 2009, 20(2):388-396.
173. Chertow G.M., Burke S.K., Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002, 62(1):245-252.
174. St Peter W.L., Liu J., Weinhandl E., Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am. J. Kidney Dis. 2008, 51(3):445-454.
175. Winkelmayer W.C., Tonelli M. Phosphate binder choice in dialysis patients: a call for evidence-based rather than marketing-based clinical practice. Am. J. Kidney Dis. 2008, 51(3):362-365.
176. Unruh M.L., Hartunian M.G., Chapman M.M., Jaber B.L. Sleep quality and clinical correlates in patients on maintenance dialysis. Clin. Nephrol. 2003, 59(4):280-288.
177. Trespalacios F.C., Taylor A.J., Agodoa L.Y., Abbott K.C. Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int. 2002, 62(5):1799-1805.
178. Herzog C.A., Strief J.W., Collins A.J., Gilbertson D.T. Cause-specific mortality of dialysis patients after coronary revascularization: why don't dialysis patients have better survival after coronary intervention?. Nephrol. Dial. Transplant. 2008, 23(8):2629-2633.
179. Hemmelgarn B.R., Southern D., Culleton B.F., et al. Survival after coronary revascularization among patients with kidney disease. Circulation 2004, 110(14):1890-1895.
180. London G.M., Marchais S.J., Guerin A.P., Metivier F. Impairment of arterial function in chronic renal disease: prognostic impact and therapeutic approach. Nephrol. Dial. Transplant. 2002, 17(Suppl. 11):13-15.
181. Weiner D.E., Sarnak M.J. Managing dyslipidemia in chronic kidney disease. J. Gen. Intern. Med. 2004, 19(10):1045-1052.
182. Rostand S.G., Kirk K.A., Rutsky E.A. Dialysis-associated ischemic heart disease: insights from coronary angiography. Kidney Int. 1984, 25(4):653-659.
183. London G.M., Marchais S.J., Guerin A.P., et al. Arterial structure and function in end-stage renal disease. Nephrol. Dial. Transplant. 2002, 17(10):1713-1724.
184. Klassen P.S., Lowrie E.G., Reddan D.N., et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 2002, 287(12):1548-1555.
185. Tozawa M., Iseki K., Iseki C., Takishita S. Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int. 2002, 61(2):717-726.
186. DeLoach S.S., Townsend R.R. Vascular stiffness: its measurement and significance for epidemiologic and outcome studies. Clin. J. Am. Soc. Nephrol. 2008, 3(1):184-192.
187. Blacher J., Safar M.E., Guerin A.P., et al. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int. 2003, 63(5):1852-1860.
188. Amann K., Tyralla K., Gross M.L., et al. Cardiomyocyte loss in experimental renal failure: prevention by ramipril. Kidney Int. 2003, 63(5):1708-1713.
189. Amann K., Breitbach M., Ritz E., Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J. Am. Soc. Nephrol. 1998, 9(6):1018-1022.
190. Bergeron S., Hillis G.S., Haugen E.N., et al. Prognostic value of dobutamine stress echocardiography in patients with chronic kidney disease. Am. Heart J. 2007, 153(3):385-391.
191. King S.B., Smith S.C., Hirshfeld J.W., et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J. Am. Coll. Cardiol. 2008, 51(2):172-209.
192. Shoji T., Emoto M., Tabata T., et al. Advanced atherosclerosis in predialysis patients with chronic renal failure. Kidney Int. 2002, 61(6):2187-2192.
193. Nishizawa Y., Shoji T., Maekawa K., et al. Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 2003, 41(3 Suppl. 1):S76-S79.
194. O'Rourke R.A., Brundage B.H., Froelicher V.F., et al. American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation 2000, 102(1):126-140.
195. Qunibi W.Y., Nolan C.A., Ayus J.C. Cardiovascular calcification in patients with end-stage renal disease: A century-old phenomenon. Kidney Int. Suppl. 2002, (82):73-80.
196. Apple F.S., Murakami M.M., Pearce L.A., Herzog C.A. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002, 106(23):2941-2945.
197. Havekes B., van Manen J.G., Krediet R.T., et al. Serum troponin T concentration as a predictor of mortality in hemodialysis and peritoneal dialysis patients. Am. J. Kidney Dis. 2006, 47(5):823-829.
198. Khan N.A., Hemmelgarn B.R., Tonelli M., et al. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation 2005, 112(20):3088-3096.
199. Sharma R., Gaze D.C., Pellerin D., et al. Cardiac structural and functional abnormalities in end stage renal disease patients with elevated cardiac troponin T. Heart 2006, 92(6):804-809.
200. Freda B.J., Tang W.H., Van Lente F., et al. Cardiac troponins in renal insufficiency: review and clinical implications. J. Am. Coll. Cardiol. 2002, 40(12):2065-2071.
201. Zannad F., Kessler M., Lehert P., et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 2006, 70(7):1318-1324.
202. Charytan D., Kuntz R.E. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int. 2006, 70(11):2021-2030.
203. Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N. Engl. J. Med. 1998, 339(8):489-497.
204. Cice G., Ferrara L., D'Andrea A., et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J. Am. Coll. Cardiol. 2003, 41(9):1438-1444.
205. Berger A.K., Duval S., Krumholz H.M. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J. Am. Coll. Cardiol. 2003, 42(2):201-208.
206. Keeley E.C., Kadakia R., Soman S., et al. Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes. Am. J. Cardiol. 2003, 92(5):509-514.
207. Winkelmayer W.C., Levin R., Setoguchi S. Associations of kidney function with cardiovascular medication use after myocardial infarction. Clin. J. Am. Soc. Nephrol. 2008, 3(5):1415-1422.
208. Kottgen A., Russell S.D., Loehr L.R., et al. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J. Am. Soc. Nephrol. 2007, 18(4):1307-1315.
209. Go A.S., Yang J., Ackerson L.M., et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 2006, 113(23):2713-2723.
210. U.S. Renal Data System, USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2007, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
211. Stewart G.A., Foster J., Cowan M., et al. Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int. 1999, 56(6):2248-2253.
212. Martin L.C., Barretti P., Cornejo I.V., et al. Influence of fluid volume variations on the calculated value of the left ventricular mass measured by echocardiogram in patients submitted to hemodialysis. Ren. Fail. 2003, 25(1):43-53.
213. Prisant L.M., Kleinman D.J., Carr A.A., et al. Assessment of echocardiographic left ventricular mass before and after acute volume depletion. Am. J. Hypertens. 1994, 7(5):425-428.
214. Astor B.C., Yi S., Hiremath L., et al. N-terminal prohormone brain natriuretic peptide as a predictor of cardiovascular disease and mortality in blacks with hypertensive kidney disease: the African American Study of Kidney Disease and Hypertension (AASK). Circulation 2008, 117(13):1685-1692.
215. Satyan S., Light R.P., Agarwal R. Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am. J. Kidney Dis. 2007, 50(6):1009-1019.
216. Haapio M., Ronco C. BNP and a renal patient: emphasis on the unique characteristics of B-type natriuretic peptide in end-stage kidney disease. Contrib. Nephrol. 2008, 161:68-75.
217. The Digitalis Investigation Group The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med. 1997, 336(8):525-533.
218. Rutsky E.A., Rostand S.G. Treatment of uremic pericarditis and pericardial effusion. Am. J. Kidney Dis. 1987, 10(1):2-8.
219. Rostand S.G., Rutsky E.A. Pericarditis in end-stage renal disease. Cardiol. Clin. 1990, 8(4):701-707.
220. Gunukula S.R., Spodick D.H. Pericardial disease in renal patients. Semin. Nephrol. 2001, 21(1):52-56.
221. Buselmeier T.J., Davin T.D., Simmons R.L., et al. Treatment of intractable uremic pericardial effusion. Avoidance of pericardiectomy with local steroid instillation. JAMA 1978, 240(13):1358-1359.
222. Abbott K.C., Agodoa L.Y. Hospitalizations for bacterial endocarditis after initiation of chronic dialysis in the United States. Nephron 2002, 91(2):203-209.
223. Marr K.A., Sexton D.J., Conlon P.J., et al. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann. Intern. Med. 1997, 127(4):275-280.
224. Little M.A., O'Riordan A., Lucey B., et al. A prospective study of complications associated with cuffed, tunnelled haemodialysis catheters. Nephrol. Dial. Transplant. 2001, 16(11):2194-2200.
225. Stevenson K.B., Hannah E.L., Lowder C.A., et al. Epidemiology of hemodialysis vascular access infections from longitudinal infection surveillance data: predicting the impact of NKF-DOQI clinical practice guidelines for vascular access. Am. J. Kidney Dis. 2002, 39(3):549-555.
226. McCarthy J.T., Steckelberg J.M. Infective endocarditis in patients receiving long-term hemodialysis. Mayo Clin. Proc. 2000, 75(10):1008-1014.
227. Doulton T., Sabharwal N., Cairns H.S., et al. Infective endocarditis in dialysis patients: new challenges and old. Kidney Int. 2003, 64(2):720-727.
228. Robinson D.L., Fowler V.G., Sexton D.J., et al. Bacterial endocarditis in hemodialysis patients. Am. J. Kidney Dis. 1997, 30(4):521-524.
229. Maraj S., Jacobs L.E., Kung S.C., et al. Epidemiology and outcome of infective endocarditis in hemodialysis patients. Am. J. Med. Sci. 2002, 324(5):254-260.
230. Umana E., Ahmed W., Alpert M.A. Valvular and perivalvular abnormalities in end-stage renal disease. Am. J. Med. Sci. 2003, 325(4):237-242.
231. Maher E.R., Young G., Smyth-Walsh B., et al. Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet 1987, 2(8564):875-877.
232. Forman M.B., Virmani R., Robertson R.M., Stone W.J. Mitral anular calcification in chronic renal failure. Chest 1984, 85(3):367-371.
233. Ribeiro S., Ramos A., Brandao A., et al. Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Nephrol. Dial. Transplant. 1998, 13(8):2037-2040.
234. London G.M., Pannier B., Marchais S.J., Guerin A.P. Calcification of the aortic valve in the dialyzed patient. J. Am. Soc. Nephrol. 2000, 11(4):778-783.
235. Urena P., Malergue M.C., Goldfarb B., et al. Evolutive aortic stenosis in hemodialysis patients: analysis of risk factors. Nephrologie 1999, 20(4):217-225.
236. Perkovic V., Hunt D., Griffin S.V., et al. Accelerated progression of calcific aortic stenosis in dialysis patients. Nephron Clin. Pract. 2003, 94(2):c40-c45.
237. Herzog C.A., Ma J.Z., Collins A.J. Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC/AHA practice guidelines on valve selection be modified?. Circulation 2002, 105(11):1336-1341.
238. Edwards F.H., Peterson E.D., Coombs L.P., et al. Prediction of operative mortality after valve replacement surgery. J. Am. Coll. Cardiol. 2001, 37(3):885-892.
239. Vazquez E., Sanchez-Perales C., Borrego F., et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am. Heart J. 2000, 140(6):886-890.
240. Abbott K.C., Trespalacios F.C., Taylor A.J., Agodoa L.Y. Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality. BMC Nephrol. 2003, 4(1):1.
241. Van Gelder I.C., Hagens V.E., Bosker H.A., et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med. 2002, 347(23):1834-1840.
242. Hagens V.E., Ranchor A.V., Van Sonderen E., et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) study. J. Am. Coll. Cardiol. 2004, 43(2):241-247.
243. Carlsson J., Miketic S., Windeler J., et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J. Am. Coll. Cardiol. 2003, 41(10):1690-1696.
244. Kasiske B.L. Hyperlipidemia in patients with chronic renal disease. Am. J. Kidney Dis. 1998, 32(5 Suppl. 3):S142-S156.
245. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch. Intern. Med. 1988, 148(1):36-69.
246. Schaefer E.J., Lamon-Fava S., Cohn S.D., et al. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J. Lipid Res. 1994, 35(5):779-792.